REG - Theracryf PLC - Manufacturing Scale Up of Lead Ox-1 Programme

TheracryfAnnouncement

17/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250717:nRSQ3793Ra&default-theme=true

RNS Number : 3793R  Theracryf PLC  17 July 2025

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

Manufacturing Scale Up of Lead Ox-1 Development Programme

 

Alderley Park, 17 July 2025 - TheraCryf plc (AIM: TCF), the clinical stage
drug development company focussing on brain disorders, provides an update on
key activity in its Ox-1 development programme.

 

At the recent AGM the Company gave an update on its lead asset Ox-1,
TheraCryf's orexin 1 antagonist in addictive behaviours, highlighting the
on-track progress made following the fundraising in March of this year to take
the programme to clinical readiness.

 

The Company now reports that manufacturing and early development partner,
Pharmaron, has initiated the manufacturing scale up of the active
pharmaceutical ingredient (API) of the lead programme, Ox-1, on-time and
to-plan. The production of the demonstration and toxicology batches, at 0.5kg
and 10kg scale, respectively, are key milestones in the development programme.
These batches will produce sufficient quantities of product for formulation,
characterisation and toxicology, all of which are essential for inclusion in
the regulatory documentation for obtaining permission to conduct trials in
people.

 

Dr Helen Kuhlman, CBO of TheraCryf commented:

"Manufacturing at scale for the first time represents a major step forward in
any development programme at this stage. The start of this activity by our
early development partner on time is another demonstration of our confidence
in both the programme and our management of it. Unlocking the considerable
future value of our addiction programme is our first priority given the large
addressable market for our Ox-1 asset."

-Ends-

Enquiries

 TheraCryf plc                                       +44 (0)1625 315 090

 Dr Huw Jones, CEO                                   enquiries@theracryf.com

 Toni Hänninen, CFO

 Dr Helen Kuhlman, CBO

 Singer Capital Markets (NOMAD & Joint Broker)       +44 (0)20 7496 3000
 Phil Davies / Oliver Platts / Patrick Weaver

 Turner Pope Investments (Joint Broker)              +44 (0)20 3657 0050

 James Pope / Andy Thacker

 Vigo Consulting                                     +44 (0)20 7390 0230

 Rozi Morris                                         theracryf@vigoconsulting.com

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain
disorders. The Company has a broad clinical and preclinical pipeline in
indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma*
and neurodevelopmental disorders [*orphan indication].

 

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. It also has
a number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know-how for
programmes from companies such as Shire (now Takeda).

 

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

 

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the
ticker symbol TCF. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPURCMUPAGQQ